Eli Lilly’s retatrutide cut nearly 30 pounds on the lowest 4 mg weekly dose in Phase 3 trial
AI Market Summary
Eli Lilly's Phase 3 Triumph-4 data for retatrutide show substantial weight loss even at the lowest dose and meaningful A1C improvement, supporting a differentiated "triple agonist" profile ahead of a planned FDA submission early next year. The update strengthens expectations for a competitive next-generation obesity/diabetes franchise, though GI side effects and noted neurological events remain key tolerability considerations that could influence label and uptake.
Impact level
● Medium
Affected assets
NCSKLLY2USD/USDT+1.75%
AI Insight · NCSKLLY2USD/USDTAI Insight
▲ Bullish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Eli Lilly’s triple-receptor agonist retatrutide (GLP-1/GIP/glucagon) delivered substantial weight loss in the Phase 3 Triumph-4 trial. Patients on the lowest 4 mg once-weekly dose lost an average of 29.8 pounds (12.7%), while those on the highest dose lost 49.6 pounds (20.8%). The company expects to submit the drug to the U.S. FDA for approval early next year, positioning it as the first therapy in its class to target all three metabolic receptors.
